Glenmark Pharmaceuticals has informed about media release titled: ‘Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)’.
The above information is a part of company’s filings submitted to BSE.